Lineage stock rises after announcing cell therapy program to treat vision loss

Apr. 25, 2022 11:07 AM ETLineage Cell Therapeutics, Inc. (LCTX)By: Ravikash, SA News Editor3 Comments

Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples

gorodenkoff/iStock via Getty Images

  • Lineage Cell Therapeutics (NYSE:LCTX) announced a new cell therapy development program, photoreceptor neural cell (PNC) transplants to treat vision loss due to photoreceptor dysfunction or damage.
  • The company said it filed for intellectual property protection covering the composition and methods for generating PNCs.
  • Lineage added that based on in vivo data generated using the PNCs, these cells may be capable of forming reconstructed retina with high survivability and neural connectivity to surrounding functional layers.
  • Lineage said it is the company's fifth cell therapy program.
  • LCTX is +6.36% to $1.25
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.